Inhibitor

CI-DRUG-00000303Explore in graph →NCIt C154898 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Activating Mutation1
Inhibitor	Malignant Pancreatic Neoplasm

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

EPOR Overexpression1
Inhibitor	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	submitted	EID7206 EPOR overexpression in B-ALL is associated with the Philadelphia-like subtype of the disease (although high EPOR expression can also be observed in B-ALL with t(12;21)-ETV6-RUNX1). In this study, EPO… (full text at CIViC) PMID 26859458 · Iacobucci et al., 2016 · Open in CIViC	civic